当前位置：
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2017-11-18 , DOI: 10.1056/nejmoa1713137 Jean-Charles Soria 1 , Yuichiro Ohe 1 , Johan Vansteenkiste 1 , Thanyanan Reungwetwattana 1 , Busyamas Chewaskulyong 1 , Ki Hyeong Lee 1 , Arunee Dechaphunkul 1 , Fumio Imamura 1 , Naoyuki Nogami 1 , Takayasu Kurata 1 , Isamu Okamoto 1 , Caicun Zhou 1 , Byoung Chul Cho 1 , Ying Cheng 1 , Eun Kyung Cho 1 , Pei Jye Voon 1 , David Planchard 1 , Wu-Chou Su 1 , Jhanelle E. Gray 1 , Siow-Ming Lee 1 , Rachel Hodge 1 , Marcelo Marotti 1 , Yuri Rukazenkov 1 , Suresh S. Ramalingam 1
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2017-11-18 , DOI: 10.1056/nejmoa1713137 Jean-Charles Soria 1 , Yuichiro Ohe 1 , Johan Vansteenkiste 1 , Thanyanan Reungwetwattana 1 , Busyamas Chewaskulyong 1 , Ki Hyeong Lee 1 , Arunee Dechaphunkul 1 , Fumio Imamura 1 , Naoyuki Nogami 1 , Takayasu Kurata 1 , Isamu Okamoto 1 , Caicun Zhou 1 , Byoung Chul Cho 1 , Ying Cheng 1 , Eun Kyung Cho 1 , Pei Jye Voon 1 , David Planchard 1 , Wu-Chou Su 1 , Jhanelle E. Gray 1 , Siow-Ming Lee 1 , Rachel Hodge 1 , Marcelo Marotti 1 , Yuri Rukazenkov 1 , Suresh S. Ramalingam 1
Affiliation
|
Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation–positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125.)
中文翻译：
奥西替尼在未经治疗的EGFR突变晚期非小细胞肺癌中的治疗
奥西替尼在EGFR突变阳性晚期NSCLC的一线治疗中显示出优于标准EGFR-TKIs的功效，具有相似的安全性和较低的严重不良事件发生率。（由阿斯利康资助； FLAURA ClinicalTrials.gov编号，NCT02296125。）
更新日期：2018-01-11
中文翻译：
奥西替尼在未经治疗的EGFR突变晚期非小细胞肺癌中的治疗
奥西替尼在EGFR突变阳性晚期NSCLC的一线治疗中显示出优于标准EGFR-TKIs的功效，具有相似的安全性和较低的严重不良事件发生率。（由阿斯利康资助； FLAURA ClinicalTrials.gov编号，NCT02296125。）
京公网安备 11010802027423号